The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention’s National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer-related and treatment-related side-effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one-half (53%) of survivors were diagnosed within the past 10 years, and two-thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non-small cell lung cancer, 49% for stages I-II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409-436.

中文翻译：

---

2022 年癌症治疗和生存统计

由于人口的增长和老龄化以及早期检测和治疗的进步，美国癌症幸存者的数量持续增加。为了帮助公共卫生界更好地为这些人服务，美国癌症协会和国家癌症研究所每三年合作一次，使用来自监测、流行病学和最终结果癌症登记处、生命统计数据的发病率和生存数据来估计美国的癌症患病率来自疾病控制和预防中心的国家卫生统计中心，以及来自美国人口普查局的人口预测。基于国家癌症数据库中的信息的当前治疗模式按种族列出了最流行的癌症类型，还简要描述了癌症相关和治疗相关的副作用。2022 年 1 月 1 日，超过 1800 万有癌症病史的美国人（830 万男性和 970 万女性）还活着。三种最常见的癌症是前列腺癌（3,523,230 例）、皮肤黑色素瘤（760,640 例）以及结肠癌和直肠癌（726,450）男性和乳房（4,055,770），子宫体（891,560）和甲状腺（823,800）女性。超过一半 (53%) 的幸存者在过去 10 年内被诊断出，三分之二 (67%) 的幸存者年龄在 65 岁或以上。治疗中最大的种族差异之一是直肠癌，41% 的 I 期疾病黑人患者接受直肠切除术或直肠结肠切除术，而白人患者的这一比例为 66%。黑人非小细胞肺癌患者的手术收入也大大降低，I-II 期为 49%，III 期为 16%，而白人患者分别为 55% 和 22%。在大多数癌症中，黑人患者被诊断为 I 期疾病的可能性仍然低于白人患者，女性乳腺癌（53% 对 68%）和子宫内膜癌（59 % 与 73%）。尽管有越来越多的工具可以帮助患者、护理人员和临床医生应对癌症生存的各个阶段，但仍需要进一步的循证策略和公平获取可用资源，以减轻有色人种社区的差异并优化对癌症患者的护理。有癌症病史的人。在大多数癌症中，黑人患者被诊断为 I 期疾病的可能性仍然低于白人患者，女性乳腺癌（53% 对 68%）和子宫内膜癌（59 % 与 73%）。尽管有越来越多的工具可以帮助患者、护理人员和临床医生应对癌症生存的各个阶段，但仍需要进一步的循证策略和公平获取可用资源，以减轻有色人种社区的差异并优化对癌症患者的护理。有癌症病史的人。在大多数癌症中，黑人患者被诊断为 I 期疾病的可能性仍然低于白人患者，女性乳腺癌（53% 对 68%）和子宫内膜癌（59 % 与 73%）。尽管有越来越多的工具可以帮助患者、护理人员和临床医生应对癌症生存的各个阶段，但仍需要进一步的循证策略和公平获取可用资源，以减轻有色人种社区的差异并优化对癌症患者的护理。有癌症病史的人。CA 癌症 J 临床。2022；72:409-436。